The total number randomized, and gender distribution were not consistently reported
In the phase 2 trial, participants began experiencing notable reductions in body weight as early as 24 weeks, with the higher-dose groups (8 mg and 12 mg) demonstrating the most pronounced changes
No fillers, excipients, or preservatives are used in the lyophilization process
The peptide is not approved as a drug and has not undergone the rigorous safety and efficacy evaluation required for pharmaceutical approval
Access to this page required Community+ Membership
Lee PHA, Ohtake T, Zaiou M, Murakami M, Rudisill JA, Lin KH, Gallo RL: Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection